Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results

(2020) Renata Ferrarotto et al.   CLINICAL CANCER RESEARCH

Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).

(2020) Naomi Kiyota et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

(2020) Myriam Chalabi et al.   NATURE MEDICINE

Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity

(2020) Lauren K. Zebertavage et al.   Scientific Reports

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma

(2020) Brendan Curti et al.   Journal for ImmunoTherapy of Cancer

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

(2020) Ravindra Uppaluri et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

(2020) Sean McBride et al.   JOURNAL OF CLINICAL ONCOLOGY

Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival

(2020) Chi T. Viet et al.   ORAL ONCOLOGY

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma

(2020) Jonathan D. Schoenfeld et al.   JAMA Oncology

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

(2018) T R Cottrell et al.   ANNALS OF ONCOLOGY

Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy

(2018) Ariel E. Marciscano et al.   CLINICAL CANCER RESEARCH

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial

(2018) Yungan Tao et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity

(2018) Marka R. Crittenden et al.   Scientific Reports

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

(2018) Maura L Gillison et al.   LANCET

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Erratum to ‘Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy’ [Oral Oncol. 61 (2016) 166–176]

(2017) R. Bryan Bell et al.   ORAL ONCOLOGY

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

(2016) Michael B. Bernstein et al.   Nature Reviews Clinical Oncology

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma

(2016) Todd Crocenzi et al.   Journal for ImmunoTherapy of Cancer

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy

(2016) Kristina H. Young et al.   PLoS One

Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy

(2015) Michael J Gough et al.   Immunotherapy

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Clavien-Dindo Classification of Surgical Complications

(2009) Pierre A. Clavien et al.   ANNALS OF SURGERY